Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Methylnaltrexone Bromide |
Synonyms | |
Therapy Description |
Relistor (methylnaltrexone bromide) is a mu-type opioid receptor inhibitor and is approved for constipation, but it has also been shown to inhibit VEGFRs and angiogenesis (PMID: 16820176). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Methylnaltrexone Bromide | Relistor | MNTX | VEGFR Inhibitor (Pan) 36 | Relistor (methylnaltrexone bromide) is a mu-type opioid receptor inhibitor and is approved for constipation, but it has also been shown to inhibit VEGFRs and angiogenesis (PMID: 16820176). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01015222 | Phase I | Methylnaltrexone Bromide Dasatinib Paclitaxel Bevacizumab | Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT04083651 | Phase II | Methylnaltrexone Bromide | A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer | Withdrawn | USA | 0 |